> 首页 > 产品 > 一抗 > 其他 > Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab)

Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab)

Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab) is 94.41%, determined by SEC-HPLC.
To measure the binding ability of Acasunlimab in hu-4-1BB-His. Acasunlimab bound to 4-1BB protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Acasunlimab bound to hu-4-1BB-His, and the EC50 was 0.007 nM.
To measure the binding ability of Acasunlimab in hu-PD-L1-His. Acasunlimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Acasunlimab bound to hu-PD-L1-His, and the EC50 was 0.042 nM.
Acasunlimab bound to hu4-1BB-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Acasunlimab bound to hu4-1BB-CHO-K cells, and the EC50 was 3.592 nM.
Acasunlimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Acasunlimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.153 nM.
Co-incubation of Acasunlimab with 4-1BB-NF-κB-Jurkat cells, then with the addition of huPD-L1-CHO-K cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Acasunlimab was able to activate the NF-κB signaling pathway, and the EC50 was 0.341 nM.
Co-incubation of Acasunlimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Acasunlimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 1.875 nM.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q07011 & Q9NZQ7
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	B7-H1 / PD-L1 / CD274,TNFRSF9 / 4-1BB / CD137
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.